

1 **Risk scores for predicting HIV incidence among adult heterosexual**  
2 **populations in sub-Saharan Africa: a systematic review and meta-analysis**

3 Katherine M. Jia<sup>1</sup>, Hallie Eilerts<sup>2</sup>, Olanrewaju Edun<sup>1</sup>, Kevin Lam<sup>1</sup>, Adam Howes<sup>3</sup>, Matthew L.  
4 Thomas<sup>4</sup>, Jeffrey W. Eaton<sup>1§</sup>

5

6 <sup>1</sup> MRC Centre for Global Infectious Disease Analysis, School of Public Health, Imperial  
7 College London, London, United Kingdom

8 <sup>2</sup> Department of Population Health, The London School of Hygiene and Tropical Medicine,  
9 London, United Kingdom

10 <sup>3</sup> Department of Mathematics, Imperial College London, London, United Kingdom

11 <sup>4</sup> Joint Centre for Excellence in Environmental Intelligence, University of Exeter & Met  
12 Office, Exeter, United Kingdom

13

14 <sup>§</sup>Corresponding author: Jeffrey W. Eaton

15

16 MRC Centre for Global Infectious Disease Analysis, School of Public Health  
17 Imperial College London  
18 St. Mary's Hospital Campus  
19 Norfolk Place  
20 London W2 1PG  
21 United Kingdom  
22 +44 20 7594 3007  
23 [jeffrey.eaton@imperial.ac.uk](mailto:jeffrey.eaton@imperial.ac.uk)

24

25 E-mail addresses of authors:

26 KMJ: [katherine.jia19@imperial.ac.uk](mailto:katherine.jia19@imperial.ac.uk)

27 HE: [hallie.eilerts@lshtm.ac.uk](mailto:hallie.eilerts@lshtm.ac.uk)

28 OE: [o.edun19@imperial.ac.uk](mailto:o.edun19@imperial.ac.uk)

29 KL: [kevin.lam@imperial.ac.uk](mailto:kevin.lam@imperial.ac.uk)

30 AH: [a.howes19@imperial.ac.uk](mailto:a.howes19@imperial.ac.uk)

31 MLT: [M.L.Thomas@exeter.ac.uk](mailto:M.L.Thomas@exeter.ac.uk)

32 JWE: [jeffrey.eaton@imperial.ac.uk](mailto:jeffrey.eaton@imperial.ac.uk)

33

34 Keywords: risk scores, HIV incidence, sub-Saharan Africa, adolescent girls and young  
35 women, risk factors for HIV incidence

36

37 Word count: Abstract: 355/350 words; Main text: 4957/5000 words

## 38 **Abstract**

39 **Introduction:** Several HIV risk scores have been developed to identify individuals for  
40 prioritised HIV prevention in sub-Saharan Africa. We systematically reviewed HIV risk  
41 scores to: (i) identify factors that consistently predicted incident HIV infection, (ii) review  
42 inclusion of community-level HIV risk in predictive models, and (iii) examine predictive  
43 performance.

44 **Methods:** We searched nine databases from inception until February 15, 2021 for studies  
45 developing and/or validating HIV risk scores among the heterosexual adult population in  
46 sub-Saharan Africa. Studies not prospectively observing seroconversion or recruiting only  
47 key populations were excluded. Record screening, data extraction, and critical appraisal  
48 were conducted in duplicate. We used random-effects meta-analysis to summarise hazard  
49 ratios and the area under the receiver-operating characteristic curve (AUC-ROC).

50 **Results:** From 1563 initial search records, we identified 14 risk scores in 13 studies. Seven  
51 studies were among sexually active women using contraceptives enrolled in randomised-  
52 controlled trials, three among adolescent girls and young women (AGYW), and three  
53 among cohorts enrolling both men and women. Consistently identified HIV prognostic  
54 factors among women were younger age (pooled adjusted hazard ratio: 1.62 [95%  
55 Confidence Interval: 1.17, 2.23], compared to above-25), single/not cohabiting with primary  
56 partners (2.33 [1.73, 3.13]) and having sexually transmitted infections (STIs) at baseline  
57 (HSV-2: 1.67 [1.34, 2.09]; curable STIs: 1.45 [1.17; 1.79]). Among AGYW only STIs were  
58 consistently associated with higher incidence, but studies were limited (n=3). Community-  
59 level HIV prevalence or unsuppressed viral load strongly predicted incidence but were only  
60 considered in three of 11 multi-site studies. The AUC-ROC ranged from 0.56 to 0.79 on the  
61 model development sets. Only the VOICE score was externally validated by multiple  
62 studies, with pooled AUC-ROC 0.626 [0.588, 0.663] ( $R^2$ : 64.02%).

63 **Conclusions:** Younger age, non-cohabiting, and recent STIs were consistently identified  
64 as predicting future HIV infection. Both community HIV burden and individual factors should  
65 be considered to quantify HIV risk. However, HIV risk scores had only low-to-moderate  
66 discriminatory ability and uncertain generalisability, limiting their programmatic utility.  
67 Further evidence on the relative value of specific risk factors, studies populations not  
68 restricted to 'at-risk' individuals, and data outside South Africa will improve the evidence  
69 base for risk differentiation in HIV prevention programmes.

70 **PROSPERO Number:** CRD42021236367

## 71 **Introduction**

72 Efficiently identifying populations and individuals at high risk of HIV infection and linking  
73 them to effective HIV prevention is essential for continued progress towards ending HIV as  
74 a public health threat [1]. Differentiating HIV prevention based on risk of infection is  
75 especially important for interventions that are expensive and intensive for both the client  
76 and the health system, such as daily oral pre-exposure prophylaxis (PrEP) [2-5]. Identifying  
77 those at highest risk for infection is most difficult in sub-Saharan Africa, where 58% of the  
78 1.5 million global new infections in 2020 occurred [6], and a large proportion of new  
79 infections were through heterosexual transmission among the general population [7].

80 Several HIV incidence risk scores have been proposed as prognostic tools for identifying  
81 individuals at high risk for HIV infection in sub-Saharan Africa [8, 9]. HIV risk scores  
82 combine data on multiple prognostic factors into a single score that summarises an  
83 individual's risk for infection. Certain interventions might be offered, or restrict eligibility to,  
84 individuals with scores above a specified threshold [10]. An optimal threshold maximises  
85 the share of incident infections among the higher risk group while minimizing the total  
86 proportion classified as such, but there is typically a trade-off between these. Risk scores  
87 are empirically derived using data from large-scale, longitudinal studies like HIV  
88 randomised controlled trials (RCTs) and cohort studies that collect comprehensive HIV  
89 prognostic factors spanning the behavioural, sociodemographic, partnership domains  
90 among HIV negative adults and prospectively measure HIV incidence, usually within 1 year  
91 or less after the baseline risk assessment. Generalisability is validated by applying the risk  
92 score to independently collected data and studying how well the score discriminates those  
93 who subsequently acquire HIV.

94 Recently, national HIV programmes have focused on prioritising interventions to  
95 geographic areas with high HIV burden [1], but not widely implemented risk scoring tools to  
96 differentiate individual-level access to HIV interventions. The geographically focused  
97 strategy is epidemiologically justified for two reasons: high HIV burden indicates previous

98 high HIV risk, and, secondly, high HIV prevalence or unsuppressed HIV viraemia implies  
99 greater exposure to HIV infection among those currently at risk [11, 12]. This community-  
100 level exposure does not fit naturally into the individual-level risk framework of risk scoring.  
101 Mathematical modelling has demonstrated that considering both geographic location and  
102 risk populations in prioritising of HIV prevention improves the efficiency and cost-  
103 effectiveness relative to only one dimension [13]. The new Global AIDS Strategy 2021-  
104 2026 embraces this approach—recommending that HIV prevention is prioritised for various  
105 population groups differentiated according to thresholds for the local HIV incidence [14].  
106 For example, for adolescent girls and young women (AGYW), the strategy recommends  
107 prioritisation of services to those at high risk based on: (i) the subnational annual incidence  
108 greater than 3%, or (ii) an incidence of 1-3% and self-reported high-risk behaviours or  
109 recent sexually transmitted infection (STI) [14].

110 We conducted a systematic review of HIV risk score tools in sub-Saharan Africa to explore  
111 this from both perspectives. Firstly, to motivate improved modelling of HIV incidence and  
112 prioritising of HIV prevention, we sought to identify prognostic factors from the HIV risk  
113 score literature that stratify population HIV risk, and the ability of these factors to  
114 discriminate HIV incidence within a population. Secondly, we queried the extent to which  
115 HIV risk scores considered community-level HIV prevalence or population viraemia as a  
116 predictor in prognostic models for individual HIV incidence risk. Specifically, we searched  
117 literature for studies that either developed or validated a HIV incidence risk score model  
118 among adult heterosexual populations, and analysed the data to: (i) identify risk factors that  
119 have consistently shown strong effects on HIV incidence across different models and  
120 settings, (ii) evaluate whether community-level HIV prevalence has been considered as a  
121 determinant of HIV risk in risk score development, and (iii) examine the efficiency of risk  
122 scores in differentiating high- and low-risk individuals quantified by the area under the  
123 receiver-operating characteristic curve (AUC-ROC).

## 124 **Methods**

125 **Search strategy.** We searched for studies that developed and/or validated the HIV  
126 incidence risk scores among adult heterosexual populations of sub-Saharan Africa.  
127 Specific inclusion criteria were: (i) development and/or validation of any predictive  
128 multivariable model (“risk score”) with prospectively measured HIV incidence as the main  
129 outcome (i.e., documented HIV-negative status at baseline), (ii) enrolled from adult  
130 heterosexual populations and (iii) conducted in sub-Saharan African countries. Studies  
131 were excluded if: (i) HIV seroconversions were not determined by a HIV negative test result  
132 at baseline followed by a positive or negative result during follow-up, (ii) study populations  
133 were key or selected populations only (men who have sex with men, female sex workers,  
134 pregnant women, serodiscordant couples, HIV-exposed infants, people who inject drugs).  
135 Keywords, synonyms, and related terms covered the domains of “sub-Saharan Africa”,  
136 “HIV/AIDS”, and “risk score”. The full electronic search strings for all databases are  
137 available in the Supplementary Material (Appendix I). No restrictions were imposed on the  
138 types nor years of publications; however, only publications written in English were included.

139 **Sources of information.** Nine databases were searched: MEDLINE, Embase, Global  
140 Health, PsycINFO, Maternity & Infant Care Database, CINAHL (EBSCO), Scopus,  
141 Cochrane Library, the Web of Science, on 15<sup>th</sup> February 2021.

142 **Study selection.** Titles and abstracts were independently screened by two reviewers for  
143 eligibility against the inclusion and exclusion criteria. Discrepancies were resolved by either  
144 consensus after discussion or decision of a third reviewer. After abstract screening, full  
145 texts were reviewed for inclusion by two independent reviewers. Reasons were provided  
146 for any exclusion of studies at this stage. Again, any discrepancies in decisions or reasons  
147 were resolved through discussion or by a third reviewer. Abstract screening, full text review,  
148 and data extraction were conducted by KMJ, HE, OE, KL, AH, and MJT.

149 **Data extraction and risk of bias assessment.** Data were extracted by two independent  
150 reviewers, with discrepancies resolved through discussion. We referred to the Critical  
151 Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies  
152 (CHARMS) Checklist when creating the data extraction form (Appendix II).<sup>[15]</sup> After  
153 extraction, two reviewers assessed the risks of bias for each study independently using the  
154 Prediction Model Risk of Bias (PROBAST) assessment tool checklist,<sup>[16]</sup> under the four  
155 domains ‘Population’, ‘Predictor’, ‘Outcome’ and ‘Analysis.’ A domain where one or more  
156 criteria was/were not fulfilled might be judged as “high risk of bias,” whereas a study with  
157 one (or more) domain(s) at “high risk of bias” would be judged as having an overall “high”  
158 risk of bias.

159 **Data synthesis and reporting.** We aimed to identify significant and measurable  
160 prognostic factors that define high risk groups or individuals for prioritised HIV prevention.  
161 We first summarised the key characteristics, setting, and study population(s) of each  
162 included study, and whether it developed a risk score, externally validated a score, or both.  
163 A development study could conduct internal validation by using re-sampling methods  
164 (bootstrap or cross-validation) to estimate the AUC-ROC, or by splitting the sample into  
165 training and testing sets; external validation where the risk score was applied to a different  
166 study population than which it was originally derived can be performed in the same analysis  
167 or by others in follow-up studies. We then assessed the importance of each predictor by  
168 examining (i) the number of times it was included in the final risk prediction model of a  
169 model development study, (ii) the summary of the adjusted and unadjusted effect size  
170 estimates. Finally, we summarised the area under the receiver operating characteristic  
171 curve (AUC-ROC), proportion identified “high risk” by each score, and the corresponding  
172 HIV incidence in the high-risk group, to assess the risk scores discrimination and compared  
173 them across settings to examine generalisability.

174 Overall summary effect size estimates (and the 95% confidence interval) for predictors  
175 were estimated by a random effects model. Estimates were pooled for both the adjusted

176 and unadjusted effects because adjusted effects were only available in studies that  
177 included the particular predictors in the multivariable models (due to significant univariate  
178 association), risking biasing summary estimates away from null. Between-study variance  
179 were reported with the  $I^2$  statistics to evaluate the heterogeneity. Random effects meta-  
180 analysis based on the inverse variance method with Sidik-Jonkman estimator for between-  
181 study variance was done in R (version 4.0.3) [17] using the packages “meta” and “metafor”  
182 [18, 19]. Meta-analysis for AUC-ROC was performed using methods described by Zhou  
183 and colleagues in Medcalc (version 19.8) [20, 21]. Forests plots and funnel plots were  
184 created using the package “meta” and Medcalc respectively.

185 The systematic review protocol was pre-registered on PROSPERO (CRD42021236367)  
186 [22]. We referred to the PRISMA (Preferred Reporting Items for Systematic Reviews and  
187 Meta-Analyses) checklist for presenting the review [23].

## 188 **Results**

189 Database searches identified 2029 records; 466 duplicates were removed and 1563 titles  
190 and/or abstracts were screened, of which 25 studies were retained for full-text screening.  
191 One additional conference abstract was available after initial screening, resulting in 13  
192 studies (9 peer-reviewed articles, 2 posters, 1 editorial letter, 1 abstract) that met the  
193 inclusion criteria and were included in this review (Figure 1) [8, 9, 24-34]. Critical appraisal  
194 according to the PROBAST checklist concluded that one out of twelve models developed  
195 and two out of nine validated were of low risk of bias (Figure S1, Table S3 & S4).  
196 Inadequate adjustment for over-fitting or model optimism was common among the  
197 development studies (6 out of 9). For the validation studies, inadequate sample size (4 of 9)  
198 and missing predictors (5 of 9) were common limitations. Among studies that reported  
199 information about loss-to-follow-up and incomplete data (9 of 15 studies; Table S5), the  
200 proportion of enrolled participants included in final analysis ranged from 80% to over 95%  
201 in the RCTs (except for one) and 60% in RCCS open-cohort study. The three studies with  
202 data from population cohorts used imputation to account for missing data and Ayton  
203 imputed unavailable predictor variables (Table S5).

204 **Study populations.** Studies were conducted in South Africa (n=10), Uganda (n=4), Malawi,  
205 Zimbabwe (n=3), Kenya (n=2), Zambia (n=1), and Tanzania (n=1). Three enrolled multi-  
206 country study populations, and eight were multi-site within one country (Table 1). A total of  
207 134,423 individuals (301,820 person-years) were included in the studies, among whom  
208 28.0% (N=37599; 73,955 person-years) were from South Africa. One study in Uganda and  
209 Kenya accounted for 56% of all participants (75,558 individuals) [33]. The mean HIV  
210 incidence was 4.82 per 100 person-years in studies conducted in South Africa and 2.34 per  
211 100 person-years elsewhere. Incidence and risk factor data were collected before 2012 for  
212 seven studies (mean incidence: 4.61 per 100 person-years) and after 2012 for six (mean  
213 incidence: 3.16 per 100 person-years). The majority (10 of 13) were among women only, of  
214 which three were restricted to young women under age 25 or lower; 3 included women and

215 men aged 15–49 years or 15 years and older. The majority (10 of 13) were RCTs or quasi-  
216 experimental studies that restricted recruitment and/or eligibility to specific at-risk  
217 population groups: (i) sexually active, contraception-seeking women who attended the  
218 family-planning, STIs or research clinics (7 of 10, all RCTs) [8, 9, 24-28], or (ii) school-  
219 attending AGYW (3 of 10) [29-31]. The remaining three were large-scale cohort studies or  
220 community trials that recruited all consenting members within the communities [32-34].  
221 Geographic locations, study periods, age groups, and settings are given in Table 1.

222 **Factors included in HIV risk scores.** Nine studies reported on development of 14 HIV risk  
223 scores, involving screening and model selection for baseline predictors of HIV incidence  
224 (Table 1). Balzer used a machine learning approach, specifically the Super Learner  
225 ensemble model method [35], which did not yield effect estimates for individual risk factors  
226 [33]. Final regression results were also not available for Roberts (abstract only) [34]. For  
227 the remaining studies, Table 2 reports the predictors considered for inclusion and retained  
228 in the final model for each independently developed score. The '*retainment ratio*' reports  
229 the number of times a risk factor was retained in the final score relative to the number of  
230 times it was considered as a '*candidate*' predictor, tabulated separately for risk scores for  
231 women of all ages and for AGYW only study populations.

232 All of the four risk scores for all age, sexually active, contraceptive-seeking women were  
233 developed using RCT data in South Africa (VOICE included data from other countries but  
234 81% of study participants were from South Africa). Factors retained in all or three of four  
235 final models were: not being married or cohabiting with primary partner (pooled adjusted  
236 hazard-ratio [aHR] 2.33; 95% CI [1.73, 3.13]; Table S6); younger age (pooled aHR: 1.62  
237 [1.17, 2.23]; less than 25 years old except for Peebles [9] at 27 years), and curable STIs at  
238 baseline (pooled aHR 1.45 [1.17, 1.79]) (Figure 2). Human Simplex Virus – 2 (HSV-2;  
239 pooled aHR 1.67 [1.34, 2.09]) and multiple sexual partners (Pooled aHR: 1.62 [1.27, 2.07])  
240 were included in two of four risk scores. Other demographic, partnership, biological or  
241 community factors were either seldom considered as candidate predictors or only retained

242 in one or fewer risk scores (Table 2). Among unselected candidate predictors, educational  
243 attainment, employment (or earning own income) and coital frequency were considered by  
244 all four studies but not retained in any of the final models (Table S1, Supplementary  
245 Materials).

246 Three risk scores were developed specifically for sexually active AGYW (aged 13-24,  
247 varying across studies) (Table 2). HSV-2 was the only factor selected in all three (pooled  
248 aHR: 1.77 [1.24; 2.54]). Factors selected in two of three models were curable STIs (pooled  
249 aHR: 2.14 [1.40; 3.25]), having multiple partners (pooled aHR: 1.76 [1.19; 2.60]) and  
250 partner having other sexual partners (pooled aHR: 2.35 [0.48; 11.53]) (Figure 3). Being not  
251 married/cohabitating was not selected in any final models, unlike the models for all age  
252 contraceptive-seeking women where it was selected by all models.

253 In summary, not being married or cohabiting was consistently identified and had the largest  
254 effect size estimates in studies among all-aged adult women. For AGYW presence of other  
255 STIs was most consistently selected. Of the remaining predictors, occupation, self-  
256 perceived HIV risk, partners' occupation, having new partners, engaging in high-risk sex  
257 (e.g., under alcohol use), knowledge of partner's HIV status showed significant  
258 associations but were seldom assessed [32].

259 ***Inclusion of community HIV prevalence.*** Only three of 11 multi-site studies considered  
260 community-level HIV prevalence as a covariate and all cases where considered it was  
261 selected into one or more of the final models [9, 32, 34]. In Peebles [9], compared to  
262 residing in a community with 10-15% HIV prevalence, those in a community with 16-20%  
263 prevalence had an aHR of 1.64 [1.08, 2.48], 1.71 [0.99, 2.96] for 21-25% prevalence, and  
264 1.81 [1.03, 3.19] for 26-30%. Similarly, in Kagaayi [32], an aHR of 1.03 was associated with  
265 each percentage-point increment in community prevalence for both male [0.99,1.07] and  
266 female [1.01, 1.06]. Roberts [34] also found community HIV prevalence and unsuppressed  
267 viral load to be highly predictive, but aHRs were not available.

268 **Predictive performance of the risk scores.** We identified 14 risk scores from nine model  
269 development studies (three models developed by Balzer were considered separately) [33]  
270 (Table 3). Most studies used baseline predictors to predict incidence infections observed  
271 during the following one year, with some extending to 18 months or two years (Table 3).  
272 When applied to the original data set from which it was developed, the scores had low-to-  
273 moderate AUC-ROC ranging from 0.56 to 0.79. Only the VOICE score has been externally  
274 validated in other settings. In seven validation studies with AUC-ROC estimates, the  
275 accuracy was lower (pooled AUC-ROC: 0.626 [0.588, 0.663];  $f^2$ : 64.02%) than in the  
276 internal validation (AUC-ROC: 0.69 [0.66, 0.72]) (Table 3, Figure 4). In addition to being  
277 among different study populations, it was common for one or two predictors to be missing  
278 in external validation sets (Table 3), which may have also contributed to decreased  
279 accuracy. Regarding validation of other scores, Roberts developed their risk scores in a  
280 large-scale cohort and validated them using data collected in a subsequent time period,  
281 also showing moderate discriminatory power (AUC-ROC 0.68 among female and 0.72  
282 among male; Table 3).

283 Several studies compared the discriminative power of combining multivariate risk scores  
284 versus single risk factors. Balkus [5] reported that not being married/cohabiting with primary  
285 partner alone yielded an AUC-ROC of 0.62 versus 0.69 for the full score, followed by age  
286 (0.60) and curable STIs (0.57). In a similar analysis, Peebles<sup>6</sup> found the most important  
287 predictors were age (less than 27), not being married/cohabiting and the provinces of  
288 residence. Three studies [8, 9, 28] additionally provided a “modified score” that excluded  
289 the laboratory-diagnosed STIs, which are not routinely available in most settings.

290 Removing laboratory-diagnosed STIs reduced the AUC-ROC by between one to eight  
291 percentage-points (Table 3). Roberts found that including only age, HIV prevalence, and  
292 viraemia as predictors produced an AUC-ROC of 0.65 for women compared to 0.68 when  
293 all risk factors were considered, and 0.71 for men compared to 0.72 when all risk factors  
294 were considered (Table 3).

295 ***Incidence among risk group categories.*** Most studies found that HIV incidence  
296 increased monotonically with the risk scores, except for Giovenco [29] (Table S7). Figure 5  
297 shows the proportion of participants identified as high risk compared to the percentage of  
298 incident cases contributed by the high-risk group. In six of nine external validation sets of  
299 the VOICE score with such information available (Table S7), women with a VOICE score of  
300 5 or above (having around 3 to 4 of the 7 risk factors) had incidence above 3%, the WHO-  
301 recommended threshold for PrEP prioritisation. Among studies collecting for all predictors  
302 that were intended by the VOICE score (maximum score: 11), above 60% of women  
303 scored 5 or above [8, 27, 28]. The threshold for which the observed incidence was >3%  
304 varied across populations: in South African samples, Peebles[9] found that incidence  
305 was >3% if AGYW scored 3 out of 11, while among the older sample aged 25-34 years  
306 only those scoring 6 out of 7 had incidence >3% (16.7% of the sample); in KwaZulu-Natal,  
307 Wand [25] observed >3% incidence for 88% of women enrolled in five clinical trials, while in  
308 an observational cohort only 60% (3<sup>rd</sup> quintile and above) of women had incidence >3%  
309 [34].

## 310 **Discussion**

311 Implementers of HIV programmes in high HIV prevalence settings in sub-Saharan Africa  
312 are considering how to optimise HIV prevention, including whether and how to implement  
313 HIV risk scoring tools to support identification and prioritisation of persons to receive certain  
314 interventions , especially oral PrEP and anticipated future prevention technologies. Our  
315 systematic review identified several scoring algorithms developed or validated for this  
316 purpose. Risk score development has especially focused on sexually active women of  
317 reproductive age or adolescent girls and young women. Twelve of the fifteen sources of  
318 studies included data from South Africa and all four risk scores for all-aged women were  
319 among RCTs enrolling sexually-active, contraceptive-seeking women in South Africa. Only  
320 three studies included men and women [32-34]. Among sexually active women of all ages,  
321 younger age, not being married/cohabiting, and having a history of STIs (at baseline or  
322 lifetime, both laboratory-confirmed and self-reported) were consistently identified as  
323 prognostic factors. Among sexually active AGYW, history of STIs remained consistently  
324 selected, but importantly being single/non-cohabiting was not consistently identified. Of the  
325 three studies including men, only one reported effect estimates for specific risk factors, with  
326 age, education, partner's occupation, partner's HIV status, numbers of partners, alcohol  
327 before sex, male medical circumcision, STIs, community type, and community HIV  
328 prevalence found to be significantly associated with HIV acquisition [32].

329 Risk scoring based on multiple predictors can improve efficiency in identifying individuals at  
330 higher risk of acquiring HIV compared to using individual risk factors [9, 36], but the  
331 improvement was only marginal (<0.1 increase in AUC-ROC) [36]. HIV incidence increased  
332 steadily with risk score in both development and validation studies, but the ability of risk  
333 scores to predict HIV incidence was only moderate. AUC-ROC values ranged from 0.56 to  
334 0.79. AUC-ROC measures the discriminative power of the risk score defined as the  
335 probability that a risk score can successfully predict a HIV incident case from a case-and-  
336 control pair [37]. An AUC-ROC equal to 1 implies the model perfectly discriminates those

337 who will acquire HIV and those who do not, while 0.5 implies the model has no  
338 discriminative power. Most were lower than the AUC-ROC of scores developed for specific  
339 populations of sero-discordant couples (AUC-ROC: 0.70 [0.64, 0.76] and 0.76 [0.70,0.83]  
340 for two external validation) [38], men-having-sex-with-men in Kenya (0.76 [0.71,0.80];  
341 derivation set) [39], and pregnant and post-partum women in Kenya (0.84 [0.72, 0.95] for  
342 derivation set; 0.73 [0.57,0.90] for internal validation set) [40]. The VOICE score was the  
343 only model externally validated by multiple studies (nine). Predictive performance of VOICE  
344 varied greatly across studies, even among those with all the predictors collected from  
345 women seeking contraceptives, which is the original intended population. Among AGYW-  
346 only populations, the discriminative power of the VOICE score is expected to be lower  
347 because one of the factors, younger age, is fulfilled by everyone in the sample.

348 Only three of eleven multisite studies considered community-level HIV prevalence or  
349 viraemia as a prognostic factor, but all showed it being highly predictive [9, 32, 34]. This  
350 supports recommendations to consider both community-level exposure and individual  
351 factors to assess individual HIV risk and optimal prevention options. In fact, Roberts found  
352 that adding factors beyond community viraemia and age only modestly improved predictive  
353 ability, questioning the added value of potentially burdensome screening for more detailed  
354 risk behaviours [34]. In contrast, in their analysis adjusted for study sites, Balkus identified  
355 non-cohabitation as the most predictive factor, but additional covariates also substantially  
356 improved predictions [8]. Further data across multiple settings to adjudicate the added  
357 value of more detailed individual risk assessment will help guide HIV programme  
358 implementation strategies.

359 The implication of the only moderate discrimination is that any use of risk scores to  
360 determine eligibility for certain prevention modalities will either restrict access for a large  
361 share of individuals who are at risk for future infection or require either setting a very low  
362 threshold score to ensure a high proportion of infections are included. In the latter case, the  
363 burden of implementing the screening tool may not outweigh the benefit, if only a relatively

364 small share of the population are ultimately screened out. Rather than restricting eligibility,  
365 another potential use of risk scores may be as a tool to prompt discussion about HIV  
366 prevention to individuals or in settings where it might otherwise not be offered. The  
367 consistently identified risk factors offer some promise this could be valuable. The threshold  
368 for such an offer could be differentiated according to local context: a relatively high  
369 threshold in settings with low community prevalence or viraemia and a lower threshold in  
370 areas with higher community exposure.

371 ***Discriminatory ability of risk scores.*** There are several possible reasons risk scores  
372 based on well-established risk factors are only moderately discriminative. First, HIV risk  
373 can change rapidly over short time intervals with life course events. Risk assessed at  
374 baseline may only be moderately predictive of an individual's actual HIV risk six to twelve  
375 months later. Individuals identified as low risk at baseline may become high-risk over the  
376 time due to changes in their behaviours, their partners' behaviours, or migration into new  
377 communities. Second, risk of acquiring HIV depends not only on individual-level risk factors  
378 but also predictors related to their partners and communities. Consequently, adults with  
379 behaviour considered 'low risk', such as a single cohabiting sex partner, could still be  
380 exposed to high risk of HIV infection if their partner acquires HIV. While the HIV incidence  
381 rate among this group is relatively low, they may contribute a large proportion of total new  
382 infections, fundamentally limiting the extent to which HIV prevention can be optimised  
383 without specific, timely, and accurate information about risk among sexual partners. Both  
384 the number of partners and partner having other partners were significantly associated with  
385 HIV acquisition in around half of the reported risk scores (Table 2). Third, factors included  
386 in risk scores are susceptible to reporting or measurement errors to varying degrees.  
387 Recent STI, identified through laboratory diagnosis in the clinical trials used for risk score  
388 development, was the most consistently identified predictive factor for HIV infection.  
389 However, laboratory testing for STIs is not routinely available in most low- and middle-  
390 income countries, where they were typically diagnosed through syndromic management

391 instead. In our review, validation studies using self-reported or syndromic identified STIs  
392 [27, 28, 30] had similar accuracy (AUC-ROCs) as those using laboratory tests [9] (Table 3),  
393 but elsewhere syndromic management has consistently had only low to moderate accuracy  
394 [41-43].

395 **Limited generalisability of risk scores.** Generalising and applying the risk scores  
396 reviewed here across high burden settings faces several challenges. First, data were  
397 disproportionately from South Africa, which has unique HIV epidemiology and low rates of  
398 marriage and cohabitation compared to neighbouring countries. Risk factors consistently  
399 identified to be significant for sexually active, contraceptive-seeking women (younger age,  
400 non-cohabitation and STIs), were all from South African studies. These may not generalise  
401 to other settings with higher marriage rates and younger age at marriage.

402 Second, some data used to develop and validate risk scores were relatively old, with about  
403 half of studies completed before 2012 when HIV incidence was higher and ART coverage  
404 lower. Rapid scale-up of ART, commensurate changes in community-level unsuppressed  
405 viral load, and shifting distribution of new infections to older ages have affected exposure to  
406 HIV infection, and consequently risk associated with individual characteristics may have  
407 changed over time and vary across settings. Considering how transmission dynamics  
408 interact with identified risk factors will be important to ensure context appropriate focusing  
409 of HIV prevention in a continually evolving epidemic [44].

410 Third, seven out of thirteen studies focused on the sexually active, contraceptive-seeking  
411 women enrolled in RCTs, who were intentionally selected as relatively high-risk for testing  
412 novel HIV prevention technologies. They excluded those who did not attend STI or family  
413 clinics (for studies based on clinical sites) and who intended to be pregnant within one or  
414 two years. External validation of the VOICE score by Giovenco (2019) demonstrated that  
415 the score did not generalise to school-attending AGYW, a majority of whom were young  
416 and not cohabiting with a primary partner, but also not sexually active at baseline  
417 assessment [29].

418 Fourth, there were subtle differences in definition and coding of risk factors across studies.  
419 This undermines the appropriateness of our pooled risk ratio estimates. In many validation  
420 studies, some selected risk factors were not available or defined differently [26, 29, 30].  
421 Inconsistencies in defining and measuring certain risk factors like the partnership and  
422 behavioural factors may have resulted in some important but inconsistently reported  
423 predictors being overlooked.

424 **Methodological challenges.** More generally, developing risk scores for HIV incidence is  
425 fundamentally challenging, resulting in moderate to high assessed risk of bias using the  
426 PROBAST checklist (Table S3). As HIV infection is a relatively uncommon event, in most  
427 studies the ratio of cases observed to risk factors considered was far lower than  
428 recommended. Many studies were limited in accounting for over-fitting and model optimism,  
429 clarity about handling missing data [16]. Our review was also constrained by incomplete  
430 reporting of multivariate regression results of initial and final models in some studies. Only  
431 a few studies compared the AUC-ROC of the full models with that of individual predictors,  
432 making it difficult to draw conclusions about the necessity of detailed risk assessment  
433 compared to a few key characteristics—a key question for HIV programme implementation.  
434 Finally, we only focused on the heterosexual adult population and did not consider risk  
435 scores among key and vulnerable populations with high incidence. Other epidemiological  
436 evidence strongly supports prioritisation and provision of HIV prevention for these groups  
437 where they can be identified.

438 **Future research priorities.** Our review identified three priorities for future studies. First,  
439 comparison of the AUC-ROCs of the full model versus individual predictors or more  
440 parsimonious models will help differentiate key predictors for identifying risk groups and  
441 prioritising resources and the relative value of factors that are more invasive or intensive to  
442 collect. Use of machine-learning techniques has also showed a potential to improving  
443 prediction accuracy and can be incorporated into some prevention interventions [45].  
444 Second, additional risk score development and validation using recent incidence data from

445 wider geographic settings will increase the generalisability of HIV risk scores. Finally,  
446 although in our review all AUC-ROCs in the external validation studies fell below 0.7,  
447 classified as poor discrimination by some [37], the discrimination of the risk scores may be  
448 higher when applied outside selected RCT populations that include not sexually individuals  
449 who would likely be screened out by risk scores, but were systematically excluded from the  
450 study populations. Alternately, individuals not sexually active at a baseline risk assessment,  
451 but who become active, could be an important risk population missed by the studies in our  
452 review. This could be explored through modelling, and further extended to study the  
453 infections averted, resources saved, and cost effectiveness of incorporating multivariable  
454 risk scores into risk stratification and prevention strategy prioritisation, and to model  
455 counterfactuals incidence for active control trials and implementation studies [44]. Our  
456 findings inform such analyses by providing data on the incidence rate ratios and proportion  
457 of infections among each group compared to the size of the group.

## 458 **Conclusions**

459 Several risk scores have been developed for identifying individuals at increased risk for HIV  
460 among general populations in sub-Saharan Africa. Among sexually active, contraceptive-  
461 seeking women, these studies have consistently identified younger age, not being  
462 married/cohabiting and STIs as risk factors. These consistently identified risk factors may  
463 be useful to prompt discussions or offers of efficacious HIV prevention. However, taken  
464 together, the programmatic benefit of implementing HIV risk scores as screening or triaging  
465 tools may be limited due to only moderate overall discriminatory ability and limited  
466 improvement compared to focusing on geographic areas with high HIV burden and basic  
467 demographics such as age group. The marginal benefits must be balanced with additional  
468 administrative burden for providers and consideration for whether screening questions  
469 could be perceived as stigmatizing, invasive, or exclusionary for clients.

470 **Competing interests**

471 JWE reports grants from Bill and Melinda Gates Foundation and UNAIDS during the  
472 conduct of the study; grants from NIH, UNAIDS, and WHO and personal fees from WHO  
473 outside the submitted work. All other authors declare no competing interests.

474

475 **Authors' contributions**

476 KMJ and JWE conceptualised the review. KMJ did the initial literature search and wrote the  
477 protocol with substantial inputs from JWE. AH, HE, OE, KMJ, KL, and MT screened  
478 abstracts and full texts, extracted the data, and performed critical appraisal. KMJ performed  
479 the analysis and wrote the first draft of the manuscript with substantial inputs from JWE,  
480 OE and AH. KMJ, JWE, AH, HE, OE, KL, and MT contributed to interpretation of the results  
481 and edited the manuscript for intellectual content. All authors read and approved the final  
482 version of the manuscript.

483

484 **Acknowledgments**

485 This research was supported by the Bill & Melinda Gates Foundation (Grant numbers:  
486 OPP1190661, INV-002606, OPP1164897), UNAIDS, and the MRC Centre for Global  
487 Infectious Disease Analysis (reference MR/R015600/1), jointly funded by the UK Medical  
488 Research Council (MRC) and the UK Foreign, Commonwealth & Development Office  
489 (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2  
490 programme supported by the European Union.

491

492 We thank Natsuko Imai for providing technical guidance and support, Adam Akullian and  
493 Allen Roberts for providing useful comments and unpublished details of their study in this  
494 review.

495

496 **Additional files:**

497 Additional file 1: Risk scores for predicting HIV incidence among general population in sub-  
498 Saharan Africa: a systematic review and meta-analysis—Supplementary Materials

499 File format: PDF

500 Description: This supplementary materials contain: (i) details of search and data extraction  
501 strategies, (ii) detailed characteristics of the data sources, (iii) summary of risk of bias  
502 assessment, (iv) summary of additional analyses of study results, and (v) PRISMA  
503 checklists.

504

505 **List of abbreviations**

506 AGYW: adolescent girls and young women

507 (a)HR: (adjusted) hazard-ratio

508 AUC-ROC: area under the receiver operating characteristic curve

509 CHARMS: Critical Appraisal and Data Extraction for Systematic Reviews of Prediction

510 Modelling Studies Checklist

511 HSV-2: Human Simplex Virus – 2

512 MMC: male medical circumcision

513 PrEP: pre-exposure prophylaxis

514 PROBAST: Prediction Model Risk of Bias assessment tool checklist

515 PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses

516 RCT: randomised controlled trial

517 STI: sexually transmitted infection

518

**Table 1. Characteristics of the cohorts from which HIV risk scores were developed and/or validated**

First author (Year)	Cohort (Study design)	Develop/Validate <sup>§</sup>	Year of study	Sites	Study population	Sex	Age <sup>†</sup>	Settings	N (Total PYs)	Incidence (per 100 PYs) <sup>††</sup>
<b>Wand (2012)</b>	MIRA (RCT)	Develop**	2003-2006	Durban, KwaZulu-Natal, South Africa (2 sites)	18-49 yrs old, sexually active, non-pregnant, willing to use contraception	F	Mean: 27 IQR: 22-34	Family-planning clinics and other community-based organisation	1485‡ (2162)	6.85
<b>Wand (2018)</b>	Multiple¶ (RCT)	Develop**	2002-2012	KwaZulu-Natal, South Africa (multiple sites)	16+ yrs old, sexually active, non-pregnant, willing to use contraception	F	Median: 27 IQR: 22-33	Various clinical study sites	8982‡ (11038)	7.03
<b>Balkus (2016)</b>	VOICE (RCT)	Develop*	2009-2011	South Africa, Uganda, and Zimbabwe	18–45 yrs old, sexually active, non-pregnant, willing to use contraception	F	Median: 24 IQR: 21-29	STI clinics, family planning clinics, and post-natal clinics, community-based locations	4834 (4348)	6.05
	HPTN 035 (RCT)	Validate	2005-2009	Malawi, South Africa, Zimbabwe, and Zambia	18+ yrs old, sexually active, not (intended to be) pregnant.	F	25 (22-29)	STI clinics, family planning clinics, and post-natal clinics, community-based locations	2848 (2903)	3.38
	FEM-PrEP (RCT)	Validate	2009-2011	Kenya, South Africa, and Tanzania	sexually active, non-pregnant, 18–35 yrs old women at high risk	F	23 (20-27)	Community outreach, recruitment sites, community partners, health centres, STI clinics, HIV voluntary testing and counselling centres	1804 (1231)	4.79
<b>Balkus (2018)</b>	ASPIRE (RCT)	Validate	2012-2015	Malawi, South Africa, Uganda, and Zimbabwe	18–45 yrs old, sexually active, not (intended to be) pregnant	F	<25 (39%)	STIs, family-planning clinics	2539 (2566)	3.70
<b>Burgess (2018)</b>	CAPRISA 004 (RCT)	Develop	2007-2010	KwaZulu-Natal, South Africa (2 sites)	18-40 yrs old, sexually active women, non-pregnant, willing to use contraception	F	<25 (68%)	An urban and a rural CAPRISA research clinic	431 (660.7)	9.08
<b>Burgess (2017)</b>	FACTS 001 (RCT)	Validate	2011-2014	South Africa (9 sites)	18-30 yrs old, sexually active, non-pregnant, willing to use contraception	F	Median: 23 IQR: 20-25	9 community-based clinical trial sites	1115 (1876)	4.32
<b>Peebles (2020)</b>	ECHO (RCT)	Develop*	2015-2018	South Africa (9 sites)	18-35 yrs old, sexually active, seeking effective contraception	F	<25 (62.1%)	9 clinics over 5 provinces	5670 (5573)	5.4 (<25)
										3.4 (25+)

<b>Giovenco (2019)</b>	HPTN 068 (RCT)	Validate	2011-2012	South Africa (single site)	school-attending 13-20 yrs old AGYW	F	Median: 15 IQR: 14-17	Random sample in the rural Bushbuckridge in Mpumalanga province	2178 (2455)	1.34
<b>Rosenberg (2020)</b>	Girl Power (Quasi-experimental)	Develop*	2016-2017	Malawi (4 sites)	sexually active, 15-24 yrs old AGYW	F	<20 (58.7%)	4 public-sector health centers in Lilongwe, Malawi	795 (672)	2.08
<b>Ayton (2020)</b>	CAPRISA 007 (RCT)	Validate	2010-2012	South Africa (14 sites)	14-25 yrs old school-attending AGYW	F	Median: 17 IQR: 16-18	Grade 9 and 10 students in 14 schools in Vulindlela	971 (971)	1.85
<b>Kagaayi (2014)</b>	RCCS (Cohort)	Develop*	2003-2011	Uganda (~50 communities)	sexually active, 15-49 yrs old	F	Mean: 27.0 SD: 7.8	Communities in Rakai district	7497 (30811)	1.11
						M	Mean: 28.3 SD: 8.0		5783 (22959)	0.98
<b>Balzer (2020)</b>	SEARCH (RCT)	Develop*	2018	Kenya and Uganda (16 communities)	15+ years old residents	F	<25 (39%)	16 communities in rural Uganda and Kenya	75558 (166723)	0.27-0.37
<b>Roberts (2021)</b>	ACDIS (Cohort)	Develop**	2012-2019	Umkhanyakude district of KwaZulu-Natal, South Africa (single site)	15+ years old residents	F	-	Rural and peri-urban communities in Umkhanyakude district	11933‡ (28422)	4.20 (2012-15) 3.11 (2016-19)
						M	-		7623‡ (16449)	1.80 (2012-15) 1.16 (2016-19)

Abbreviations: **AGYW**: adolescent girls and young women; **RCT**: randomised controlled trial; **STI**: sexually transmitted infection; **N**: number; **PYs**: person-years; **yrs**: years; **F**: female; **M**: male;

§ Develop: model development (marked with \* if the authors did re-sampling procedures through cross-validation or bootstrapping to obtain the AUC-ROC for internal validation of their score(s), and \*\* if they split the sample into training and testing sets as part of their internal validation); Validate: external validation of the risk score in a study population different from which the score was originally developed. Peebles [6], Burgess (2018) [24] and Rosenberg [26] developed their own risk scores while also using their samples to externally validate the VOICE score developed by Balkus [5]; AUC-ROCs are provided in Table 3.

<sup>¶</sup> Multiple cohort studies included: MIRA, MDP 301, NCT00213083, VOICE, HPTN035. <sup>†</sup> Mean/median (IQR)

<sup>‡</sup> Total sample size is provided here, whereas the authors split the sample into training and testing sets.

<sup>††</sup> Cumulative incidence after follow-up in each study.

**Table 2. Risk factors retained in the final HIV risk score models and adjusted effect estimates**

First author (Year) Cohort	Women only, all ages (RCTs) †					AGYW only (RCT / quasi-experimental trials) †				General population‡	
	Retention ratio‡	Wand (2012) MIRA	Wand (2018) Multiple	Balkus (2016) VOICE	Peebles (2020) ECHO 25+ yrs old	Retention ratio‡	Peebles (2020) ECHO <25 yrs old	Burgess (2018) CAPRISA 004 <25 yrs old	Rosenberg (2020) GirlsPower	Kagaayi (2014) RCCS female	Kagaayi (2014) RCCS male
<b>Demographic</b>											
Age (younger)	3/4	N.I.	1.75-2.93***	1.70*	2.12*	0/3			N.I.	1.03*	0.81*
Age of sexual debut (<16 yrs)	1/1		1.38*								
Not married/living with partners	4/4	2.63**	3.62***	1.80*	1.85*	0/3	N.I.	N.I.	N.I.	1.72-2.08*	N.I.
Pregnancy history†††						1/2	N.I.		4.55*		
Parity (less)	1/3		2.62***	N.I.	N.I.	0/1	N.I.				
Education (Higher)	0/4	N.I.	N.I.	N.I.	N.I.	0/2	N.I.		N.I.	0.83^	0.56*
High-risk occupation†										1.32*	
Perceived HIV risk (High)										1.49*	
Alcohol use	1/3	N.I.		1.41*	N.I.	1/2	1.45*		N.I.		
<b>Partnership factor</b>											
Partner >5 yrs older						1/1			2.42^		
Partner in high risk occupation											1.89*
Fin. support from partner	1/3	N.I.		0.72*	N.I.	0/3	N.I.	N.I.	N.I. ††		
Partner has other partners:											
Don't know vs No	1/2			1.81*	N.I.	1/1		7.56*			
Yes vs No	1/3	N.I.		1.63*	N.I.	2/3		7.86*	N.I.		
Yes/don't know vs No							1.31^				
Partner has unknown HIV status											1.82*
No. of partners††††	2/4			N.I.	N.I.	2/3	1.61*	2.19*	N.I.	1	1
2 (ref : 1)		1.34^								1.59*	1.21*
3 (ref : 1)		1.93*									1.90*
3+ (ref: <2)			1.61***								
New sex partner										1.45*	

<b>Concurrent relationships</b>										1.50 <sup>^</sup>		
<b>Transmission probability</b>	<b>Condom use (Yes)</b>	1/3	N.I.	N.I.		N.I.	1/1	1.34 <sup>^</sup>				
	<b>Oral contraceptive (Yes)</b>	0/1		N.I.								
	<b>Injectable Contraceptive (Yes)</b>	1/1		1.43 <sup>***</sup>								
	<b>High risk sex <sup>††</sup></b>	1/1	1.96 <sup>*</sup>	-						1.44 <sup>*</sup>	1.28 <sup>*</sup>	
	<b>MMC of primary partners/ MMC (male)</b>	0/3		N.I.	N.I.	N.I.	0/2	N.I.		N.I.	0.61 <sup>*</sup>	
	<b>HSV-2 <sup>†††</sup></b>	2/4			1.63 <sup>*</sup>	1.88 <sup>*</sup>	3/3	1.51 <sup>*</sup>	2.54 <sup>*</sup>	1.94 <sup>^</sup>		
<b>STIs/ genital infection <sup>†††</sup></b>	4/4	1.60 <sup>**</sup>	1.57 <sup>***</sup>	1.49 <sup>*</sup>	2.22 <sup>*</sup>	2/3	2.07 <sup>*</sup>	N.I.	2.61 <sup>^</sup>	1.75 <sup>*</sup>	1.78 <sup>*</sup>	
<b>Community</b>	<b>Community type</b>										1.67 <sup>*</sup>	
	<b>Community prevalence</b>	0/1				N.I.	1/1	1.64 <sup>*</sup> - 1.81 <sup>*</sup>		1.03 <sup>*</sup>	1.03 <sup>*</sup>	
	<b>Province</b>	1/1				9.05 <sup>*</sup>						
<b>Adjusted for sites (Y/N)</b>			N	N	Y	Y		Y		Y	Y	
<b>AUC-ROC</b>			0.79 <sup>§§</sup>	0.71 <sup>§§</sup>	0.69 <sup>§</sup>	0.64 <sup>§</sup>		0.62 <sup>§</sup>	0.7	0.79	0.67 <sup>§</sup>	0.69 <sup>§</sup>
<b>95% CI</b>			0.70-0.81	-	0.66-0.72	0.59-0.69		0.58-0.64	0.60-0.79	0.69-0.89	0.64-0.70	0.66-0.73

**AGYW:** adolescent girls and young women; **RCT:** Randomised-controlled trial; **STI:** sexually transmitted infection; **MMC:** medical male circumcision; **HSV-2:** herpes simplex virus type 2; **AUC-ROC:** area under receiver operating characteristic curve; **ref.:** reference category; **yrs:** years; **95% CI:** 95% confidence interval; **N.I.:** not included; **Y:** Yes; **N:** No

<sup>†</sup> Women recruited from RCTs were sexually active and willing to use effective contraception during the study period

<sup>‡</sup> Balzer and Roberts also developed risk scores in their studies, but the final models were not available and thus details are not shown in Table. Risk factors considered by these analyses are reported in Table S2.

<sup>#</sup> *Retention Ratio* reports the number of times a risk factor was retained in the final score relative to the number of times it was considered as a 'candidate' predictor, tabulated separately for risk scores for women of all ages and for AGYW only study populations.

<sup>¶</sup> Detailed list of high-risk occupations is provided by Kagaayi (2014).

'N.I.' indicates risk factor was measured but not selected for inclusion in final model; Dark grey shaded cells indicate risk factor was not considered as a candidate predictor in the study; Light grey shaded cells in the *Retention Ratio* column indicates risk factor not considered by any models.

\* (p<0.05); \*\* (p<0.01); \*\*\* (p<0.0001) significant and included in the final risk score;

<sup>^</sup> (p>0.05) not significant but included

<sup>¶¶</sup> Wand (2012) considered lifetime number of sex partners, while all others considered recent number of sex partners (Table S1 contains details on temporality of sexual partners for each study). Casual partnerships (none vs at least one) among sexually-active women was considered as a proxy for multiple partners in Burgess (2018) study.

<sup>††</sup> High risk sex was defined by multiple behavioural risk factors in Wand (2012), while defined as using alcohol before sex by Kagaayi (2014).

<sup>†††</sup> Methods for STIs status assessment varied by studies; details are provided in Table S2 of the Supplementary Materials.

<sup>††</sup> Although partners' financial support from were not included in the final model, all HIV cases (n=14) in Rosenberg (2020) engaged in transactional sex.

<sup>†††</sup> Pregnancy history referred to self-reported past pregnancy event(s) in Rosenberg (2020).

<sup>§</sup> AUC-ROC was obtained through cross-validation or bootstrapping of the original derivation set for the internal validation; <sup>§§</sup> AUC-ROC was based on a "testing" set different from the "training" set for which the score was derived.

**Table 3. Predictive performance from the development and validation of included risk scores**

First author (Year)	N Dev <sup>†</sup>	Cohort (Study design)	HIV incident cases	Prediction horizon	Score developed	AUC-ROC (95% CI)	N Val <sup>††</sup>	Predictors available	Score externally validated	AUC-ROC (95% CI)
Wand (2012)	1 **	MIRA (RCT)	148	1 to 2 yrs	Wand-2012	0.79 (0.70, 0.81) **	-	-	-	-
Wand (2018)	1 **	Multiple § (RCT)	776	1 to 2+ yrs	Wand-2018	0.71 (-)**	1	-	-	-
Balkus (2016)	1 *	VOICE (RCT)	263	1 yr	VOICE	0.69 (0.66, 0.72) *	-	-	-	-
					VOICE (Modified)	0.67 (0.64, 0.70) *	1	-	-	-
		HPTN 035 (RCT)	98	1 yr			-	6/7	VOICE	0.70 (0.65, 0.75)
		FEM-PrEP (RCT)	59	1 yr			-	6/7	VOICE	0.63 (-)
							-	4/5	VOICE (Modified)	0.58 (0.51, 0.65)
Balkus (2018)	-	ASPIRE (RCT)	95	1 yr			1	5/7	VOICE	0.69 (0.64, 0.74)
Burgess (2018)	1	CAPRISA 004 (RCT)	47 (<25) 13 (25+)	18 mo	Burgess (under 25)	0.70 (0.60, 0.79)	1	All <sup>#</sup>	VOICE	0.66 (0.54, 0.74)
					Burgess (under 25) (Modified)	0.62 (0.56, 0.68)			VOICE (under 25)	0.69 (0.60, 0.78)
Burgess (2017)	-	FACTS 001 (RCT)	81	2.2 yrs			1	All <sup>#</sup>	VOICE	0.49 (0.30, 0.63) 0.56 (0.50, 0.62)
Peebles (2020)	2 *	ECHO (RCT)	188 (<25) 72 (25+)	1 yr			1	All	VOICE	0.61 (0.58, 0.65)
									VOICE (Modified)	0.59 (0.56, 0.62)
					Peebles (under-25)	0.62 (0.58, 0.64) *	-	-	-	-
					Peebles (under-25) (Modified)	0.59 (0.55, 0.61) *	-	-	-	-
					Peebles (25+)	0.64 (0.59, 0.69) *	-	-	-	-
					Peebles (25+) (Modified)	0.62 (0.58, 0.67) *	-	-	-	-
Giovenco (2019)		HPTN 068 (RCT)	33	1 yr			1	6/7	VOICE	0.55 (0.44, 0.65)
Rosenberg (2020)	1 *	Girl Power (Quasi-experimental)	14	1 yr	Rosenberg	0.79 (0.69, 0.89) *	1	-	-	-
							-	All <sup>#</sup>	VOICE	0.64 (0.52, 0.75)
Ayton (2020)	-	CAPRISA 007 (RCT)	18	1 yr			1	4/7	VOICE	-
Kagaayi (2014)	2 *	RCCS (Cohort)	342	1 yr	Kagaayi (female)	0.67 (0.64, 0.70) *	-	-	-	-
					Kagaayi (male)	0.69 (0.66, 0.73) *	-	-	-	-
Balzer (2020)	3 *	SEARCH (RCT)	519	1 yr	Balzer (Risk group-based)	0.59 (0.55, 0.62) *	-	-	-	-
					Balzer (Model-based)	0.70 (0.68, 0.73) *	-	-	-	-
					Balzer (Machine-learning)	0.73 (0.71, 0.76) *	-	-	-	-

<b>Roberts (2021)</b>	2 **	ACDIS (Cohort)	1160	1 yr	Roberts (female)	0.68 **	-	-	-	-
					Roberts (female) (age + geographic covariates only)	0.65 **				
			248	1 yr	Roberts (male)	0.72 **	-	-	-	-
					Roberts (male) (age + geographic covariates only)	0.71 **				


**N:** number; **Dev:** developed; **AUC-ROC:** Area under receiver operating characteristic curve; **RCT:** randomised controlled trial (RCT); **95% CI:** 95% confidence interval; **Val:** validated; **yr(s):** year(s); **mo:** months

<sup>†</sup>Number of risk score(s) developed (“N Dev”) / externally validated (“N Val”) by the study

\* AUC-ROC was obtained through cross-validation or bootstrapping of the original derivation set for the internal validation; \*\* AUC-ROC was based on a “testing” set different from the “training” set for which the score was derived. Wand (2012) [20] and Wand (2018) [21] did a random split of data sets, while Roberts [30] split the data by time periods (2012-2015 vs 2016-2019).

# Self-reported STIs histories or symptoms were used as proxies for curable STIs and HSV-2 status in Burgess (2017) [27] and Rosenberg [30], and for curable STIs in Burgess (2018) [28].

## Figures




**Figure 1.** HIV risk score study selection. **n:** number; **AGYW:** adolescent girls and young women (AGYW)

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


**A**

**(i) married / cohabiting**




**B**


**(i) married / cohabiting**




**(ii) age**




**(ii) age**




**(iii) multiple sexual partners**




**(iii) multiple sexual partners**




**(iv) partners having other partners**




**(iv) partners having other partners**




**(v) curable STIs**




**(v) curable STIs**



**(vi) HSV-2**



**(vi) HSV-2**




**Figure 2.** Forest plots of risk factor estimates among women in general. Adjusted (A) and unadjusted (B) effects were pooled together for: (i) marital / cohabiting status, (ii) age, (iii) number of sexual partners, (iv) partners having other partners, (v) curable sexually transmitted infection (STIs) and (vi) HSV-2. Abbreviations: **Ref:** reference category; **HR:** hazard ratio; **aHR:** adjusted hazard ratio; **95% CI:** 95% confidence interval; **STIs:** sexually transmitted infections; **HSV-2:** herpes simplex virus type 2.


It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

**A**


**(i) Not married / cohabiting**




**(ii) Multiple partners**




**(iii) Partners having other partner(s)**



**(iv) Curable STIs**




**(v) HSV-2**




**B**


**(i) Not married / cohabiting**




**(ii) Multiple partners**




**(iii) Partners having other partner(s)**




**(iv) Curable STIs**




**(v) HSV-2**



**Figure 3.** Forest plots of risk factor estimates among adolescent girls and young women (AGYW). Adjusted (A) and unadjusted (B) effects were pooled together for (i) marital / cohabiting status (ii) number of sexual partners, (iii) partners having other partners, (iv) curable sexually transmitted infection (STIs) and (v) HSV-2. Abbreviations: **Ref:** reference category; **HR:** hazard ratio; **aHR:** adjusted hazard ratio; **95% CI:** 95% confidence interval; **STIs:** sexually transmitted infections; **HSV-2:** herpes simplex virus type 2.



**Figure 4.** Forest plot (A) and funnel plot (B) for the area-under-curve of the receiver operating characteristic curves (AUC-ROCs) from external validation studies for the VOICE score. Studies with <sup>^</sup> did not collect all the predictors intended by the model (Details are in Table 3). Those with \* used self-reported STIs history, syndromic management or self-reported symptoms in place of laboratory diagnosed STIs status at baseline as intended by the original VOICE score (Details are in Table 3 and Table S2). Abbreviations: **AUC**: area under curve; **95% CI**: 95% confidence interval; **ROC**: receiver-operating characteristic.



**Figure 5.** Percentage of individuals identified as high risk among incident cases versus proportion classified as high risk for: (i) women enrolled in clinical trials (A), (ii) AGYW (B), and (iii) the general population (C). When the highest score was used as the threshold, few or none were classified as high risk and they took up a small fraction of all HIV incident cases (indicated by the origin). When the lowest score was used, all were classified as high risk and all incident cases were among them. **Dev:** Development set; **Val:** Validation set. **AGYW:** adolescent girls and young women.

## References

1. The Joint United Nations Programme on HIV/AIDS (UNAIDS). End Inequalities. End AIDS. Global AIDS Strategy 2021-2026. 2021.
2. Case KK, Gomez GB, Hallett TB. The impact, cost and cost-effectiveness of oral pre-exposure prophylaxis in sub-Saharan Africa: a scoping review of modelling contributions and way forward. *Journal of the International AIDS Society*. 2019;22(9):e25390-e.
3. Global HIV Prevention Coalition. Implementation of the HIV Prevention 2020 Road Map. 2020 [Available from: <https://www.unaids.org/en/resources/documents/2020>].
4. Global HIV Prevention Coalition. Implementation of the HIV Prevention 2020 Road Map First progress report, March 2018. 2018 [Available from: <https://www.unaids.org/en/resources/documents/2018/hiv-prevention-2020-road-map-first-progress-report>].
5. Schaefer R, Schmidt H-MA, Ravasi G, Mozalevskis A, Rewari BB, Lule F, et al. Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study. *The Lancet HIV*. 2021;8(8):e502-e10.
6. UNAIDS. Latest Global and Regional Statistics on The Status of AIDS Epidemic. 2021.
7. UNAIDS. 2021 UNAIDS Global AIDS Update — Confronting inequalities — Lessons for pandemic responses from 40 years of AIDS. 2021.
8. Balkus JE, Brown E, Palanee T, Nair G, Gafoor Z, Zhang J, et al. An Empiric HIV Risk Scoring Tool to Predict HIV-1 Acquisition in African Women. *Journal of Acquired Immune Deficiency Syndromes*. 2016;72(3):333-43.
9. Peebles K, Palanee-Phillips T, Balkus JE, Beesham I, Makkan H, Deese J, et al. Age-Specific Risk Scores Do Not Improve HIV-1 Prediction Among Women in South Africa. *Journal of acquired immune deficiency syndromes (1999)*. 2020;85(2):156-64.
10. Heffron R, Ngure K, Odoyo J, Bulya N, Tindimwebwa E, Hong T, et al. Pre-exposure prophylaxis for HIV-negative persons with partners living with HIV: uptake, use, and

effectiveness in an open-label demonstration project in East Africa. *Gates Open Research*.

2018;1(3).

11. Tanser F, Vandormael A, Cuadros D, Phillips AN, de Oliveira T, Tomita A, et al. Effect of population viral load on prospective HIV incidence in a hyperendemic rural African community. *Science translational medicine*. 2017;9(420):eaam8012.

12. Farahani M, Radin E, Saito S, Sachathep K, Hladik WA, Voetsch AC, et al. Population Viral Load, Viremia and Recent HIV-1 Infections: Findings from Population-based HIV Impact Assessments (PHIAs) in Zimbabwe, Malawi, and Zambia. *J Acquir Immune Defic Syndr*. 2021.

13. Anderson S-J, Cherutich P, Kilonzo N, Cremin I, Fecht D, Kimanga D, et al. Maximising the effect of combination HIV prevention through prioritisation of the people and places in greatest need: a modelling study. *The Lancet*. 2014;384(9939):249-56.

14. UNAIDS. *Prevailing against Pandemics: by Putting People at the Centre*. 2020.

15. Moons KGM, de Groot JAH, Bouwmeester W, Vergouwe Y, Mallett S, Altman DG, et al. Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies: The CHARMS Checklist. *PLOS Medicine*. 2014;11(10):e1001744.

16. Moons KGM, Wolff RF, Riley RD, Whiting PF, Westwood M, Collins GS, et al. PROBAST: A Tool to Assess Risk of Bias and Applicability of Prediction Model Studies: Explanation and Elaboration. *Ann Intern Med*. 2019;170(1):W1-w33.

17. R Core Team. *R: A language and environment for statistical computing*. R Foundation for Statistical Computing, Vienna, Austria. 2020 [Available from: <https://www.R-project.org/>].

18. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. *Evidence-Based Mental Health*. 2019:153-60.

19. Viechtbauer W. Conducting meta-analyses in R with the metafor package. *Journal of Statistical Software*. 2010;3:1-48.

20. Zhou XH, Obuchowski N, McClish D. *Statistical Methods in Diagnostic Medicine, Second Edition*2002.

21. MedCalc. Meta-analysis: area under ROC curve 2021 [Available from: <https://www.medcalc.org/manual/meta-analysis-ROC-area.php>.
22. Eaton J, Thomas M, Edun O, Howes A, Eilerts H, Jia K, et al. Risk scores for predicting HIV incidence among general population in sub-Saharan Africa: a systematic review. PROSPERO 2021 CRD42021236367 2021 [Available from: [https://www.crd.york.ac.uk/prospero/display\\_record.php?ID=CRD42021236367](https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021236367).
23. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.
24. Wand H, Ramjee G. Assessing and evaluating the combined impact of behavioural and biological risk factors for HIV seroconversion in a cohort of South African women. *AIDS Care*. 2012;24(9):1155-62.
25. Wand H, Reddy T, Naidoo S, Moonsamy S, Siva S, Morar NS, et al. A Simple Risk Prediction Algorithm for HIV Transmission: Results from HIV Prevention Trials in KwaZulu Natal, South Africa (2002-2012). *AIDS & Behavior*. 2018;22(1):325-36.
26. Balkus JE, Brown ER, Palanee-Phillips T, Kiweewa FM, Mgodini N, Naidoo L, et al. Performance of a Validated Risk Score to Predict HIV-1 Acquisition Among African Women Participating in a Trial of the Dapivirine Vaginal Ring. *Jaids*. 2018;77(1):E8-E10.
27. Burgess EK, Delany-Moretlwe S, Pisa P, Ahmed K, Sibiyi S, Gama C, et al. Validation of a risk score for HIV acquisition in young African women with facts 001. *Topics in Antiviral Medicine*. 2017;25 (1 Supplement 1):364s-5s.
28. Burgess EK, Yende-Zuma N, Castor D, Karim QA. An age-stratified risk score to predict HIV acquisition in young South African women. *Topics in Antiviral Medicine*. 2018;26 (Supplement 1):419s.
29. Giovenco D, Pettifor A, MacPhail C, Kahn K, Wagner R, Piwowar-Manning E, et al. Assessing risk for HIV infection among adolescent girls in South Africa: an evaluation of the VOICE risk score (HPTN 068). *Journal of the International AIDS Society*. 2019;22(7):e25359

30. Rosenberg NE, Kudowa E, Price JT, Pettifor A, Bekker L-G, Hosseinipour MC, et al. Identifying Adolescent Girls and Young Women at High Risk for HIV Acquisition: A Risk Assessment Tool From the Girl Power-Malawi Study. *Sexually Transmitted Diseases*. 2020;47(11):760-6.
31. Ayton SG, Pavlicova M, Abdool Karim Q. Identification of adolescent girls and young women for targeted HIV prevention: a new risk scoring tool in KwaZulu Natal, South Africa. *Scientific reports*. 2020;10(1):13017.
32. Kagaayi J, Gray RH, Whalen C, Fu P, Neuhauser D, McGrath JW, et al. Indices to measure risk of HIV acquisition in Rakai, Uganda. *PLoS ONE*. 2014;9(4).
33. Balzer LB, Havlir DV, Kanya MR, Chamie G, Charlebois ED, Clark TD, et al. Machine Learning to Identify Persons at High-Risk of Human Immunodeficiency Virus Acquisition in Rural Kenya and Uganda. *Clinical Infectious Diseases*. 2020;71(9):2326-33.
34. Roberts A, Cuadros D, Vandormael A, Gareta D, Barnabas R, Herbst K, et al. Predicting Risk of HIV Acquisition in Rural South Africa Using Geographic Data. *Conference on Retroviruses and Opportunistic Infections (CROI) International Antiviral Society–USA* 2021.
35. Polley E, LeDell E, Kennedy C, Lendle S, van der Laan M. SuperLearner: Super Learner Prediction 2021 [Available from: <https://cran.r-project.org/web/packages/SuperLearner/index.html>].
36. Balkus J, Palnee-Phillips T, Zhang J, Kiweewa FM, Nair G, Pather A, et al. A validated risk score to predict HIV acquisition in African women: assessing risk score performance among women who participated in the aspire trial. *AIDS research and human retroviruses*. 2016;32:49 - .
37. Hosmer DWJ, Lemeshow S, Sturdivant RX. *Applied Logistic Regression, Third Edition*: John Wiley & Sons, Inc.; 2013.
38. Kahle EM, Hughes JP, Lingappa JR, John-Stewart G, Celum C, Nakku-Joloba E, et al. An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-Serodiscordant

couples for targeted HIV-1 prevention. *Journal of Acquired Immune Deficiency Syndromes*. 2013;62(3):339-47.

39. Wahome E, Thiong'o AN, Mwashigadi G, Chirro O, Mohamed K, Gichuru E, et al. An Empiric Risk Score to Guide PrEP Targeting Among MSM in Coastal Kenya. *AIDS and Behavior*. 2018;22(1):35-44.

40. Pintye J, Drake AL, Kinuthia J, Unger JA, Matemo D, Heffron RA, et al. A Risk Assessment Tool for Identifying Pregnant and Postpartum Women Who May Benefit From Preexposure Prophylaxis. *Clin Infect Dis*. 2017;64(6):751-8.

41. Zemouri C, Wi TE, Kiarie J, Seuc A, Mogasale V, Latif A, et al. The Performance of the Vaginal Discharge Syndromic Management in Treating Vaginal and Cervical Infection: A Systematic Review and Meta-Analysis. *PLOS ONE*. 2016;11(10):e0163365.

42. Barry MS, Ba Diallo A, Diadhiou M, Mall I, Gassama O, Ndiaye Guèye MD, et al. Accuracy of syndromic management in targeting vaginal and cervical infections among symptomatic women of reproductive age attending primary care clinics in Dakar, Senegal. *Tropical Medicine & International Health*. 2018;23(5):541-8.

43. Wi TE, Ndowa FJ, Ferreyra C, Kelly-Cirino C, Taylor MM, Toskin I, et al. Diagnosing sexually transmitted infections in resource-constrained settings: challenges and ways forward. *Journal of the International AIDS Society*. 2019;22(S6):e25343.

44. Moore JR, Donnell DJ, Boily MC, Mitchell KM, Delany-Moretlwe S, Bekker LG, et al. Model-Based Predictions of HIV Incidence Among African Women Using HIV Risk Behaviors and Community-Level Data on Male HIV Prevalence and Viral Suppression. *Jaids*. 2020;85(4):423-9.

45. Marcus JL, Sewell WC, Balzer LB, Krakower DS. Artificial Intelligence and Machine Learning for HIV Prevention: Emerging Approaches to Ending the Epidemic. *Current HIV/AIDS Reports*. 2020;17(3):171-9.